Search

Your search keyword '"Teixeira, Mauro M."' showing total 142 results

Search Constraints

Start Over You searched for: Author "Teixeira, Mauro M." Remove constraint Author: "Teixeira, Mauro M." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
142 results on '"Teixeira, Mauro M."'

Search Results

1. Angiotensin-(1–7) decreases inflammation and lung damage caused by betacoronavirus infection in mice

2. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

4. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

6. Detection of Chikungunya Virus RNA in Cerebrospinal Fluid of Patients with Severe Neurological Disorders

7. Estimating the potential risk of transmission of arboviruses in the Americas and Europe: a modelling study

8. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

9. Neuromuscular defects after infection with a beta coronavirus in mice

11. PI3K Isoforms in Cell Signalling and Innate Immune Cell Responses

12. Effects of a pro‐resolving drug in COVID‐19: preclinical studies to a randomized, placebo‐controlled, phase Ib/IIa trial in hospitalized patients.

13. EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil

14. Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina

15. PAF signaling plays a role in obesity-induced adipose tissue remodeling

16. E3 Ubiquitin Ligase Smurf1 Regulates the Inflammatory Response in Macrophages and Attenuates Hepatic Damage during Betacoronavirus Infection.

17. Natural product pharmacology: the British Journal of Pharmacology perspective.

19. Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

20. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

21. Antibacterial and Antiviral Properties of Chenopodin-Derived Synthetic Peptides

22. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review.

24. Influence of previous Zika virus infection on acute dengue episode

25. Treatments for dengue: a Global Dengue Alliance to address unmet needs

26. Secondary Streptococcus pneumoniae infection increases morbidity and mortality during murine cryptococcosis

27. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

29. Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)

30. Recent changes in the British Journal of Pharmacology: widening scope and improving author and editor experience

31. GILZ Modulates the Recruitment of Monocytes/Macrophages Endowed with a Resolving Phenotype and Favors Resolution of Escherichia coli Infection

32. Secondary Streptococcus pneumoniae infection increases morbidity and mortality during murine cryptococcosis.

33. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial

34. Plasmin and plasminogen prevent sepsis severity by reducing neutrophil extracellular traps and systemic inflammation

37. Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants

38. Annexin A1-FPR2/ALX Signaling Axis Regulates Acute Inflammation during Chikungunya Virus Infection

39. Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19

41. RvD1 disrupts nociceptor neuron and macrophage activation and neuroimmune communication, reducing pain and inflammation in gouty arthritis in mice

42. Planning experiments: Updated guidance on experimental design and analysis and their reporting III

43. Corrigendum to “Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review” [Pharmacol. Res. 177 (2022) 106076]

44. Airborne Pathogen Detection in Fine Aerosol Exhaled Breath Condensates

45. Future directions for the discovery of natural product-derived immunomodulating drugs

46. Interleukin-17 Contributes to Chikungunya Virus-Induced Disease

47. Glucocorticoid-Induced Leucine Zipper Alleviates Lung Inflammation and Enhances Bacterial Clearance during Pneumococcal Pneumonia

48. Additional file 1 of EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil

49. sj-docx-1-asn-10.1177_17590914221121257 - Supplemental material for In Utero Exposure to Zika Virus Results in sex-Specific Memory Deficits and Neurological Alterations in Adult Mice

50. Angiotensin-(1-7)/MasR axis promotes migration of monocytes/macrophages with a regulatory phenotype to perform phagocytosis and efferocytosis

Catalog

Books, media, physical & digital resources